1. Esculentic acid has anti-inflammatory effect.
2. Esculentic acid has protective effects against LPS-induced endotoxic shock may be mediated, at least in part, by regulation the release of inflammatory cytokines and mediators, and protein expression of COX-2 in mice.
1. 6,7-Dihydroxycoumarin has anticoagulant effect.
2. 6,7-Dihydroxycoumarin acts as a photosensitizer for DNA damage.
3. 6,7-Dihydroxycoumarin can quench the inner fluorescence of bovine serum albumin.
1. Sinomenine exerts significant antinociceptive effects for neuropathic pain via GABAa-mediated mechanism.
2. Sinomenine shows a significant neuroprotective effects against both LPS- and MPP+-induced DA neurotoxicity, and that this protection is mediated through microglia.
3. Sinomenine inhibits cerebral water content and neurological deficit, can be used to treat Alzheimer's diseases as well as other diseases that involve neuroinflammation.
4. Sinomenium is widely used as an immunosuppressive drug for treating rheumatic and arthritic diseases via release of histamine, but other effects such as inhibition of prostaglandin, leukotriene and nitric oxide synthesis may also be involved.
1. Momordin Ic might represent a potential source of anticancer candidate, by inducing apoptosis through oxidative stress-regulated mitochondrial dysfunction involving the MAPK and PI3K-mediated iNOS and HO-1 pathways.
2. Momordin Ic and oleanolic acid obtained from KF appear to contribute to alleviating the adverse effects of CCl4 treatment by enhancing the hepatic antioxidant defense system.
3. Momordin Ic accelerates gastrointestinal transit partially by stimulating synthesis of 5-HT to act through 5-HT(2), possibly 5-HT(2C) and/or 5-HT(2B) receptors, which, in turn, increases synthesis of prostaglandins.
4. Momordin Ic inhibited gastric emptying , is relative to serum glucose and, at least in part, mediated by capsaicin-sensitive sensory nerves and the central nervous system.
1. Vitexicarpin can significantly reduce vascular inflammation, through inhibition of ROS-NF-κB pathway in vascular endothelial cells.
2. Vitexicarpin may become a potential leading drug in the therapy of prostate carcinoma.